Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29145

Title:	Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting
Authors:	VAN WIJMEERSCH, Bart Patti, F. Hobart, J. Kizlaitiene, R. Vanderdonckt, P. Shor, S. Andreasen, A. K. Uitdehaag, B. M.
Issue Date:	2019
Publisher:	WILEY
Source:	EUROPEAN JOURNAL OF NEUROLOGY, 26, p. 866-866
Notes:	[Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium. [Patti, F.] Univ Catania, Teaching Hosp Policlin, Multiple Sclerosis Ctr, Catania, Italy. [Hobart, J.] Plymouth Univ, Peninsula Sch Med, Plymouth, Devon, England. [Hobart, J.] Plymouth Univ, Peninsula Sch Dent, Plymouth, Devon, England. [Kizlaitiene, R.] Vilnius Univ, Hosp Santariskiu Clin, Ctr Neurol, Clin Neurol & Neurosurg,Fac Med, Vilnius, Lithuania. [Vanderdonckt, P.] AZ Groeninge, Kortrijk, Belgium. [Shor, S.; Andreasen, A. K.] Sanofi, Amsterdam, Netherlands. [Uitdehaag, B. M.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
Document URI:	http://hdl.handle.net/1942/29145
ISSN:	1351-5101
e-ISSN:	1468-1331
ISI #:	000474481004025
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

30

checked on Jul 28, 2023

Check